AzTrials
AzTrials

Cholangiopancreatography, Endoscopic RetrogradeNCT06689033

High Flow Nasal Oxygen Versus Standard Nasal Oxygen in Endoscopic Retrograde Cholangiopancreatography Under Sedation

An observational study of Cholangiopancreatography, Endoscopic Retrograde and Hypoxia, run by Ankara City Hospital Bilkent at 1 site in Turkey (Türkiye).

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The administration of supplemental oxygen using a standard nasal cannula is the current standard of care for patients undergoing sedation for gastrointestinal endoscopic procedures. Read more about this study

Who is it for?
Ages 18 years and older
How many people
187 participants
Where
1 siteTurkey (Türkiye)
Study dates
1 Apr 2023to 30 Nov 2023
How long will I take part?
1 Day
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: Patients scheduled for ERCP procedure under sedation in Ankara City Hospital's Gastrointestinal Endoscopy Colonoscopy Unit are included.

Who may be able to join

  • Voluntary patients over 18 years of age
  • ASA (American Society of Anaesthesiologists) I-IV risk scores

Who cannot join

  • Patients with altered mental status, dementia, cognitive disorders
  • Intubation
  • Tracheostomies
  • Need for oxygen therapy due to preexisting disease
  • Pregnancy
  • Recent history of nasal bleeding
  • Allergy to propofol

Trial locations and contacts

1 site in 1 country.

Turkey (Türkiye)1 site
  • Ankara Bilkent City Hospital, Department of Anesthesiology

    Ankara, 06800

Other trials in Turkey (Türkiye)

About this study

Official title: Comparison of High Flow Nasal Oxygen and Standard Nasal Oxygen in Preventing Hypoxia in Patients Undergoing Endoscopic Retrograde Cholangiopancreatography Under Sedation

The administration of supplemental oxygen using a standard nasal cannula is the current standard of care for patients undergoing sedation for gastrointestinal endoscopic procedures. Endoscopic Retrograde Cholangio Pancreatography can be particularly challenging for anesthesiologists due to the increased difficulty in airway access when performed in the prone position. High-flow nasal oxygen is a non-invasive oxygen therapy system that can provide heated and humidified air containing oxygen at a high flow rate.This study aims to compare the effectiveness of High Flow Nasal Oxygen versus standard nasal oxygen in preventing hypoxemia in patients undergoing deep sedation during ERCP procedures.

Read the detailed description

Ankara City Hospital's Gastrointestinal Endoscopy Colonoscopy Unit's patient count determined using G-power statistical software ensured that a sample size of at least 185 patients was adequate at a 95% confidence level with 80% power and an effect size of 0.5. Analyses were performed using the Power and Sample Size statistical program version 3.1.2 (Vanderbilt University, 2015).

187 patients scheduled for ERCP procedure under sedation during an 8-month period were included in the study. The study was planned as a randomized observational and prospective study. Patients were randomly allocated to either the nasal oxygen (NO) or High Flow Nasal Oxygen (HFNO) group in a 1:1 ratio using a computer-generated random code generator. It was not a blind study, as the oxygen delivery systems did not look the same. Endoscopists, anesthesiologists, and patients were not blinded. ERCP procedures were completed by one of two expert endoscopists and sedation was performed by one of two anesthesiologists trained in endoscopic sedation. The study and possible risks were explained to all patients participating in the study, and written informed consent was obtained from the patients. The patient's age, current chronic diseases, and duration of the procedure were recorded. Before the procedure, the frailty level of the patients was evaluated with the Modified Frailty Index-11 (mFI-11) and recorded. The mFI-11 is an 11-item index that assesses comorbidities to stratify patient risk. The simplified frailty index is calculated as the number of present comorbidities divided by the total number of 11 items used in the mFI-11 assessment, which includes diabetes mellitus, not independent functional status, chronic obstructive pulmonary disease, congestive heart failure, myocardial infarction, percutaneous coronary intervention or cardiac surgery, angina, hypertension medication, peripheral vascular disease, impaired sensorium, transient ischemic attack, and cerebrovascular accident. The resulting score ranges from 0 to 1. Patients were positioned prone and pulse oximetry, non-invasive blood pressure monitoring, electrocardiography, and Bispectral Index monitoring were performed, and baseline values were recorded in all cases. The NO group was preoxygenated with 100% oxygen for 3 min with an oxygen flow rate of 8 L.min-1 via a nasal cannula before induction and received 100% oxygen with a flow rate of 5 L.min-1 throughout the procedure. The HFNO group was preoxygenated with 100% oxygen with a flow rate of 40 L.min-1 for 3 min via an HFNO system (Inspired 02FLO High Flow Heated Respiratory Humidifier, VUN-001, Vincent Medical Manufacturing Co., Hong Kong) before induction and received 50% oxygen with a flow rate of 50 L.min-1. In case of a decrease in saturation (SpO2<90), the flow was increased to 60 L.min-1, and if it did not resolve, FiO2 was increased to 100%. All patients were premedicated with iv midazolam and sedation was performed with iv 1 µg.kg-1 fentanyl and iv bolus dose of 0.5-1 mg.kg-1 %1 propofol followed by an iv infusion of propofol 3-4 mg.kg-1.hr-1 targeting a BIS value of 60-80. In case of apnea or desaturation, maneuvers such as patient stimulation, chin lifting, or increasing oxygen flow were performed and recorded. The lowest SpO2 values obtained for both groups were noted.

The data were analyzed using IBM SPSS Statistics ver. 25 (IBM Corporation, Armonk, NY, USA). The distribution of continuous numerical variables was tested for normality using the Kolmogorov-Smirnov test, and the homogeneity of variances was assessed with Levene's test. Descriptive statistics were expressed as mean ± standard deviation or range (minimum - maximum) for continuous variables, and as case number and percentage (%) for categorical variables. The significance of differences between the NO and HFNO groups for continuous variables that met the assumptions of parametric test statistics was evaluated using Student's t-test, whereas differences for those that did not meet these assumptions were assessed using the Mann-Whitney U test. The significance of changes over time in systolic, diastolic, and mean blood pressure, heart rate, oxygen saturation (SpO2), and BIS levels was examined using repeated measures analysis of variance with Wilks' Lambda test. Where Wilks' Lambda test results were found significant, the specific times causing the differences were identified using the Bonferroni-adjusted multiple comparison test. Comparisons between the NO and HFNO groups were made by calculating the changes in SpO2 and BIS from baseline at subsequent time points. Unless otherwise stated, Pearson's χ2 test was used for the analysis of categorical data. For 2x2 contingency tables where at least 25% of the expected frequencies were below 5, Fisher's exact test was used, and where expected frequencies were between 5 and 25, the continuity-adjusted χ2 test was employed. In RxC tables (where at least one of the categorical variables in the row or column had more than two outcomes), if at least 25% of the cells had expected frequencies below 5, the Fisher-Freeman-Halton test was applied. Unless stated otherwise, results were considered statistically significant at p<0.05. However, to control for Type I error in all multiple comparisons, Bonferroni correction was applied.

Keywords
HFNO, sedation, prone position, Cholangiopancreatography, Endoscopic Retrograde
Medical subject headings
Hypoxia

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT06689033
Study groupRoleWhat they receive
Group 1: Patients sedated for ERCP, receiving nasal oxygenNasal Oxygen, preoxygenation with 100% oxygen for 3 min with an oxygen flow rate of 8 L.min-1 via a nasal cannula before induction and 100% oxygen with a flow rate of 5 L.min-1 throughout the procedure.
Group 2: Patients sedated for ERCP receiving high flow nasal oxygenHigh flow nasal oxygen, preoxygenation with 100% oxygen with a flow rate of 40 L.min-1 for 3 min before induction and received 50% oxygen with a flow rate of 50 L.min-1.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Oxygen saturation SpO2 levels of the cases in %

    Each patient was monitored with an oxygen saturation probe and SpO2 levels of the cases were recorded before induction of sedation and every 5 minutes, throughout the procedure. Hypoxemia was detected.

    Measured: Oxygen saturation levels were recorded before induction and every 5 minutes throughout the procedure that lasted around 30 minutes.

Secondary outcomes (1)
  1. Number of interventions over procedure time (number)

    In case of apnea or desaturation, airway interventions were performed and recorded throughout the procedure

    Measured: Number of maneuvers performed throughout the procedure, that lasted around 30 minutes were recorded.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted14 Nov 2024
  2. Study start1 Apr 2023
  3. Primary completion30 Nov 2023
  4. Study completion30 Nov 2023

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Case-control
Time perspective
Prospective
Enrolment
187 participants (actual)
Target duration
1 Day
IDs, dates and publications
ClinicalTrials.gov ID
NCT06689033
Sponsor's protocol ID
E2-23-4070
Status last verified
Nov 2024
First submitted
28 Oct 2024
Last updated
14 Nov 2024
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: Data will be shared after publication of the study. Study protocol, statistical analysis, study report will be shared if required by a researcher.

Publications

  • Carron M, Tamburini E, Safaee Fakhr B, De Cassai A, Linassi F, Navalesi P. High-flow nasal oxygenation during gastrointestinal endoscopy. Systematic review and meta-analysis. BJA Open. 2022 Oct 18;4:100098. doi: 10.1016/j.bjao.2022.100098. eCollection 2022 Dec.

    PubMed 37588780
  • Sawase H, Ozawa E, Yano H, Ichinomiya T, Yano R, Miyaaki H, Komatsu N, Ayuse T, Kurata S, Sato S, Pinkham MI, Tatkov S, Ashizawa K, Nagata K, Nakao K. Respiratory support with nasal high flow without supplemental oxygen in patients undergoing endoscopic retrograde cholangiopancreatography under moderate sedation: a prospective, randomized, single-center clinical trial. BMC Anesthesiol. 2023 May 8;23(1):156. doi: 10.1186/s12871-023-02125-w.

    PubMed 37158818
  • Zhang YX, He XX, Chen YP, Yang S. The effectiveness of high-flow nasal cannula during sedated digestive endoscopy: a systematic review and meta-analysis. Eur J Med Res. 2022 Feb 24;27(1):30. doi: 10.1186/s40001-022-00661-8.

    PubMed 35209948
  • Douglas N, Ng I, Nazeem F, Lee K, Mezzavia P, Krieser R, Steinfort D, Irving L, Segal R. A randomised controlled trial comparing high-flow nasal oxygen with standard management for conscious sedation during bronchoscopy. Anaesthesia. 2018 Feb;73(2):169-176. doi: 10.1111/anae.14156. Epub 2017 Nov 24.

    PubMed 29171661
  • Corral-Blanco M, Sayas-Catalan J, Hernandez-Voth A, Rey-Terron L, Villena-Garrido V. High-Flow Nasal Cannula Therapy as an Adjuvant Therapy for Respiratory Support during Endoscopic Techniques: A Narrative Review. J Clin Med. 2023 Dec 22;13(1):81. doi: 10.3390/jcm13010081.

    PubMed 38202089
  • Cha B, Lee MJ, Park JS, Jeong S, Lee DH, Park TG. Clinical efficacy of high-flow nasal oxygen in patients undergoing ERCP under sedation. Sci Rep. 2021 Jan 11;11(1):350. doi: 10.1038/s41598-020-79798-7.

    PubMed 33432035
  • Lee MJ, Cha B, Park JS, Kim JS, Cho SY, Han JH, Park MH, Yang C, Jeong S. Impact of High-Flow Nasal Cannula Oxygenation on the Prevention of Hypoxia During Endoscopic Retrograde Cholangiopancreatography in Elderly Patients: A Randomized Clinical Trial. Dig Dis Sci. 2022 Aug;67(8):4154-4160. doi: 10.1007/s10620-021-07272-z. Epub 2021 Nov 2.

    PubMed 34727281
  • Kim SH, Bang S, Lee KY, Park SW, Park JY, Lee HS, Oh H, Oh YJ. Comparison of high flow nasal oxygen and conventional nasal cannula during gastrointestinal endoscopic sedation in the prone position: a randomized trial. Can J Anaesth. 2021 Apr;68(4):460-466. doi: 10.1007/s12630-020-01883-2. Epub 2021 Jan 6.

    PubMed 33403549

Questions about this trial

What is this clinical trial studying?

An observational study of Cholangiopancreatography, Endoscopic Retrograde and Hypoxia, run by Ankara City Hospital Bilkent at 1 site in Turkey (Türkiye).

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 14 Nov 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Oxygen saturation SpO2 levels of the cases in % (time frame: Oxygen saturation levels were recorded before induction and every 5 minutes throughout the procedure that lasted around 30 minutes.). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT06689033, which also lists 8 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Nov 2024; AzTrials last refreshed its copy on 6 Nov 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in